Tharimmune signs nonbinding letter of intent to merge with intract pharma to create transformative oral biologic therapeutics company

- business combination to form a best-in-class, transformative oral biologics company - synergies between tharimmune's clinical-stage assets and intract's delivery platform to drive pipeline growth - merger anticipated to close in 1q25 bridgewater, nj and london, uk / accesswire / september 30, 2024 / tharimmune, inc. (nasdaq:thar) ("tharimmune"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, and intract pharma ltd. ("intract"), a biopharmaceutical company developing disruptive delivery solutions for oral biologics, announced today they have entered into a nonbinding, exclusive letter of intent ("loi") pursuant to which tharimmune will acquire all outstanding shares of privately-held intract in exchange for newly issued restricted common stock.
THAR Ratings Summary
THAR Quant Ranking